FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de stacks

Extended GH Stack

GH Optimizationadvanced

91

synergie

91
Share
Pépétides

3

Moyenne journalière en mcg

650

Niveau

advanced

Ajouté

May 17, 2026

Aperçu

The Extended GH Stack adds IGF-1 LR3 to the classic CJC-1295 + Ipamorelin base, creating a three-tier growth hormone axis protocol that addresses GH secretion, GH release, and downstream IGF-1 signaling simultaneously. CJC-1295 and Ipamorelin handle the upstream signaling — increasing GH output through GHRH and ghrelin pathways respectively. IGF-1 LR3 (a long-acting analog of Insulin-like Growth Factor-1) enters downstream, acting directly on muscle, bone, and organ cells to drive protein synthesis, cellular hypertrophy, and tissue growth — the actual anabolic outcomes that elevated GH is designed to produce. The practical advantage of adding IGF-1 LR3 is ensuring the anabolic signal reaches peripheral tissue even when natural liver conversion of GH to IGF-1 is suboptimal — common with age, metabolic dysfunction, or intensive training loads. IGF-1 LR3 has a 20–30 hour half-life compared to native IGF-1''s minutes, providing sustained receptor activation throughout the day. This stack is for experienced users who have established a response to the classic GH stack and want to extend its downstream effects. IGF-1 LR3 is administered post-workout to direct its anabolic action toward recently trained muscle tissue. This protocol requires blood work monitoring of IGF-1 levels (often quarterly), fasting glucose, and HbA1c due to IGF-1''s insulin-like effects on glucose metabolism.

Protocole de dose

CJC-1295

Every day· subcutaneous

Lire plus sur CJC-1295 →

300 mcg

par dose

Ipamorelin

Every day· subcutaneous

Lire plus sur Ipamorelin →

300 mcg

par dose

IGF-1 LR3

daily (post-workout)· subcutaneous

Lire plus sur IGF-1 LR3 →

50 mcg

par dose

Objectifs & Preuves

Maximum anabolismMuscle hypertrophyGH axis optimizationPerformance
Niveau d'évidence :Données humaines

Avertissements

  • IGF-1 LR3 carries significant risk if IGF-1 levels are not monitored. Contraindicated with any cancer history. Requires medical supervision.

Comments

Sign in to join the discussion

Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.